About US
Contact us
>>Back
Report reveals large untapped market for rheumatoid arthritis drugs
- Publisher：
- Publication：2012/10/23
The emergence of anti-tumour necrosis factor (anti-TNF) therapies has vastly improved the treatment of rheumatoid arthritis in recent years, but there is still a need for more effective therapies, a report has claimed.
Frost & Sullivan's latest research highlights a number of limitations of anti-TNF therapy, including its high cost, side-effects and the need for regular injections.
Unsurprisingly, biopharmaceutical companies are working to develop alternatives, having recognised the large untapped market for such products.
"While TNF inhibitors have laid the groundwork for the next generation of effective, disease-modifying anti-rheumatic treatment and biologics, the need of the hour is patient-friendly options with improved profiles, such as oral administration or enhanced tolerability," said Deborah Toscano, a senior industry analyst at Frost & Sullivan.
Ms Toscano noted that a conservative regulatory environment means any new drugs will need to benefit from a high degree of safety and significant clinical or economic advantages over anti-TNFs in order to gain market share.